Drilldown: Medicines

Other values:

Search

None (32) · Dalmane (1) · Doral (1) · Halcion (1) · Lexotan (1) · Librium (1) · Mogadon (1) · Nuplazid (1) · Onfi (1) · ProSom (1) · Restoril (1) · Rohypnol (1) · Serax (1) · Tranxene (1) · Versed (1) · Xanax (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antiparkinsonian · Antipsychotic · Empathogen · Neuroleptic · Cathinone

Other values:

Search

Apomorphine and nuciferine; dopaminergic activity (1) · Contains atropine, scopolamine, hyoscyamine (1) · Contains bufotenin and DMT (1) · Contains harmine, harmaline, tetrahydroharmine (1) · Contains ibogaine; kappa-opioid agonist (1) · Contains LSA (2) · Contains mescaline (2) · Contains muscimol and ibotenic acid (1) · Contains psilocybin and psilocin (1) · Contains salvinorin A (1) · DMT + MAOI (harmine/harmaline); 5-HT2A agonist (1) · DMT-containing plant used in psychedelic preparations (1) · Extremely potent GABAA positive allosteric modulator (1) · GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1) · GABAA positive allosteric modulator (18) · GABAA positive allosteric modulator; low sedation (1) · GABAA positive allosteric modulator; prodrug of desmethyldiazepam (1) · GABAA positive allosteric modulator; very long half-life (1) · Kavalactones; GABAA modulator; sigma receptor activity (1) · Mechanism incompletely understood (1) · Mitragynine/7-hydroxymitragynine; mu-opioid partial agonist (1) · Partial MAOI; anticholinergic effects (1) · Partial mu-opioid receptor agonist; alpha-2 agonist (1) · Potent mu-opioid receptor agonist (1) · Reversible MAO-A inhibitor; beta-carboline (1) · Reversible MAO-A inhibitor; NMDA antagonist; beta-carboline (1) · Selective inverse agonist at 5HT2A receptors with weaker activity at 5HT2C. Has no significant dopamine D2 affinity, unique among approved antipsychotics. Inverse agonism (rather than antagonism) reduces constitutive 5HT2A receptor activity below baseline. (1) · Weak serotonin reuptake inhibitor; beta-carboline (1)

None (45) · Hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Investigational for psychosis in other dementias and as augmentation for depression. (1) · '"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"' (1)

None (45) · 0.25 mg (1) · 34 mg PO once daily (1)

None (45) · 0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) · 10 mg, 34 mg capsules/tablets (1)

None (45) · 10 mg/d (1) · 34 mg/d (1)

None (45) · Oral (2)

None (45) · 30-60 min (immediate-release); 1-2 h (extended-release) (1) · Benefit over weeks of dosing (1)

None (45) · 6 h (immediate-release); ~11 h (extended-release) (1) · Daily dosing (1)

None (45) · 11-13 h (immediate-release); 11-16 h (extended-release) (1) · ~57 hours (parent), ~200 h (active metabolite) (1)

None (45) · 80-90% oral (1) · Not characterized; oral dosing once daily (1)

None (45) · Category D'"`UNIQ--ref-0000006C-QINU`"' (1) · Limited data; avoid (1)

None (45) · Rx. FDA black-box warning for increased mortality in elderly patients with dementia-related psychosis (class warning shared with all antipsychotics) (1) · Schedule IV (US) (1)